Quantum Biopharma (QNTM) Net Income towards Common Stockholders (2019 - 2026)
Quantum Biopharma (QNTM) posted Net Income towards Common Stockholders of -$2.8 million for Q1 2026, down 21.52% sequentially from -$2.3 million in Q4 2025, and up 14.23% YoY from -$2.4 million in Q1 2025.
Quantum Biopharma (QNTM) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends
Quantum Biopharma has reported Net Income towards Common Stockholders for 8 years, with the latest figure at -$2.8 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 14.23% year-over-year to -$2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$14.7 million (up 5.37% YoY) and the FY2025 annual result came in at -$27.0 million, changed N/A from the prior year.
- Net Income towards Common Stockholders declined to -$2.8 million in Q1 2026 per QNTM's latest filing, from -$2.3 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$444506.0 in Q1 2022 and troughed at -$34.8 million in Q4 2023.
- A 5-year average of -$6.0 million and a median of -$3.5 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders plunged 2115.35% in 2023, then soared 84.33% in 2024.
- Over 5 years, Net Income towards Common Stockholders stood at -$444506.0 in 2022, then slumped by 7731.08% to -$34.8 million in 2023, then jumped by 84.33% to -$5.5 million in 2024, then surged by 57.83% to -$2.3 million in 2025, then dropped by 21.52% to -$2.8 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$2.8 million, -$2.3 million, and -$5.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Quantum Biopharma | 15.44 Mn | 11.80 Mn | - | -2.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.29 Mn |
| Mar 31, 2026 | -2.80 Mn |
| Dec 31, 2025 | -2.30 Mn |
| Sep 30, 2025 | -5.34 Mn |
| Jun 30, 2025 | -4.29 Mn |
| Mar 31, 2025 | -3.26 Mn |
| Dec 31, 2024 | -5.46 Mn |
| Sep 30, 2024 | -3.83 Mn |
| Jun 30, 2024 | -3.02 Mn |
| Mar 31, 2024 | -2.08 Mn |
| Dec 31, 2023 | -34.81 Mn |
| Sep 30, 2023 | -1.06 Mn |
| Jun 30, 2023 | -5.72 Mn |
| Mar 31, 2023 | -9.85 Mn |
| Mar 31, 2022 | -444,506.00 |
| Jun 30, 2021 | -452,937.00 |
| Mar 31, 2021 | 533,842.00 |
| Sep 30, 2020 | -1.16 Mn |
| Jun 30, 2020 | -408,872.15 |
| Mar 31, 2020 | -896,464.60 |